Cheng Teng, Li Fei, Wei Rui, Lv Meng-Qin, Zhou Yin, Dai Yun, Yuan Yuan, Jiang Gui-Ying, Ma Ding, Gao Qing-Lei
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):891-894. doi: 10.1007/s11596-017-1823-8. Epub 2017 Dec 21.
The application of prostate-specific antigen (PSA) in the screening and diagnosis of prostate cancer (PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26 (MMP26) is a member of matrix metalloproteinases (MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay (ELISA) in 160 subjects including PCa group (n=80), benign prostatic hyperplasia (BPH) group (n=40) and control group (n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.
前列腺特异性抗原（PSA）在前列腺癌（PCa）筛查和诊断中的应用改善了PCa患者的临床管理。然而，PSA检测因其与惰性患者的过度诊断及后续过度治疗的潜在关联而受到批评。基质金属蛋白酶-26（MMP26）是基质金属蛋白酶（MMPs）家族的一员，据报道在许多癌症中高表达。本研究评估了血清MMP26作为PCa生物标志物的潜力。采用酶联免疫吸附测定（ELISA）法检测了160名受试者的血清MMP26水平，其中包括PCa组（n = 80）、良性前列腺增生（BPH）组（n = 40）和对照组（n = 40）。此外，我们通过免疫组织化学评估了MMP26在组织中的表达。结果显示，PCa组血清MMP26水平显著高于BPH组和对照组。同样，MMP26蛋白在PCa组织中呈阳性，而在BPH组织和对照组织中呈阴性。总之，这些结果表明MMP26可作为PCa诊断中一种潜在的血清生物标志物。
